Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

459.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
62 63 Next >
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade.
These stocks offer attractive risk-reward profiles. 
Via The Motley Fool
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
It's been a crazy year across sectors, but winners remain. 
Via The Motley Fool
Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture?
Via Benzinga
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
With a new medicine on the market and plenty of money, Vertex is in great shape. 
Via The Motley Fool
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
3 Monster Stocks to Buy Without Any Hesitation
These are easy choices for investors seeking market-beating long-term gains. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
Editas isn't out of the woods yet, but it's better off than before. 
Via The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
The stock has been in the news lately. 
Via The Motley Fool
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
5 Top Stocks to Buy With Your End-of-the-Year Bonus
Your bonus could become the gift that keeps on giving. 
Via The Motley Fool
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
Should you consider NASDAQ:VRTX for quality investing?
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. 
Via Chartmill
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
Vertex shares have climbed about 40% this year. 
Via The Motley Fool
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
Better Growth Stock: Archer Aviation or Prime Medicine?
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
The benefits from its first drug launch will trickle in slowly, at least at first. 
Via The Motley Fool
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
This biotech could have more winners on the way. 
Via The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review
The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests. 
Via Investor's Business Daily
Topics Economy Stocks
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS